- AstraZeneca has reiterated its full-year guidance following a first half performance in line with forecasts.

The group said the residual effects of the Crestor and Seroquel XR loss of exclusivity in the US had an impact on product sales which fell to $9,783m - down 11% at actual exchange rates.

Total revenues of $10,456m were down 11% at actual exchange rates and 10% at constant currencies.

Reported operating profit rose to $1,842m - up 37% at actual exchange rates and 22% at constant currencies.

Core operating profits of $3,215m were up 7% at actual exchange rates and 3% at constant currencies.

The first half dividend is maintained at $0.90 per share.

Chief executive Pascal Soriot said: "Our performance in the first half was in line with expectations as we experience the loss of exclusivity of Crestor and Seroquel XR in the US.

"We continued to deliver transformative science across the pipeline, particularly in Oncology.

"Imfinzi was launched in bladder cancer while we published practice-changing data in breast cancer for Lynparza, our first-in-class PARP inhibitor.

"In lung cancer, we strengthened our unique portfolio focused on both the genetic drivers of disease and immunotherapy. In the first half, we shared positive results for Imfinzi in the PACIFIC trial and reported more encouraging data for Tagrisso in patients with central nervous system metastases.

"I'm excited about our pipeline-driven transformation as we continue to deliver for shareholders on our strategy to return to sustainable long-term growth.

"In a pivotal year for AstraZeneca, we remain focused on realising the potential of our pipeline, growing our new launch medicines and bringing our strong science to patients."

At 8:02am: [LON:AZN] AstraZeneca PLC share price was -256.25p at 4856.75p

Story provided by